These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
687 related articles for article (PubMed ID: 18567516)
21. Opioid-induced respiratory effects: new data on buprenorphine. Dahan A Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215 [TBL] [Abstract][Full Text] [Related]
22. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363 [TBL] [Abstract][Full Text] [Related]
23. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. Davis MP J Support Oncol; 2012; 10(6):209-19. PubMed ID: 22809652 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130 [TBL] [Abstract][Full Text] [Related]
25. A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain. Mitra F; Chowdhury S; Shelley M; Williams G Pain Med; 2013 Jan; 14(1):75-83. PubMed ID: 23320402 [TBL] [Abstract][Full Text] [Related]
26. Introduction of low dose transdermal buprenorphine -- did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Skurtveit S; Furu K; Kaasa S; Borchgrevink PC Eur J Pain; 2009 Oct; 13(9):949-53. PubMed ID: 19095476 [TBL] [Abstract][Full Text] [Related]
27. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666 [TBL] [Abstract][Full Text] [Related]
28. Buprenorphine and the transdermal system: the ideal match in pain management. Budd K Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010 [TBL] [Abstract][Full Text] [Related]
30. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481 [TBL] [Abstract][Full Text] [Related]
31. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Sittl R; Nuijten M; Nautrup BP Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481 [TBL] [Abstract][Full Text] [Related]
32. Buprenorphine TDS: the clinical development rationale and results. Radbruch L; Vielvoye-Kerkmeer A Int J Clin Pract Suppl; 2003 Feb; (133):15-8; discussion 23-4. PubMed ID: 12665119 [TBL] [Abstract][Full Text] [Related]
33. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843 [TBL] [Abstract][Full Text] [Related]
34. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307 [TBL] [Abstract][Full Text] [Related]
36. Buprenorphine TDS: use in daily practice, benefits for patients. Radbruch L Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120 [TBL] [Abstract][Full Text] [Related]
37. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Koltzenburg M; Pokorny R; Gasser UE; Richarz U Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645 [TBL] [Abstract][Full Text] [Related]
38. Transdermal opioids for cancer pain. Cachia E; Ahmedzai SH Curr Opin Support Palliat Care; 2011 Mar; 5(1):15-9. PubMed ID: 21325999 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. Ruggiero A; Coccia P; Arena R; Maurizi P; Battista A; Ridola V; Attinà G; Riccardi R Pediatr Blood Cancer; 2013 Mar; 60(3):433-7. PubMed ID: 23034996 [TBL] [Abstract][Full Text] [Related]
40. [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy]. Zhen ZJ; Sun XF; Xia Y; Ling JY; Zheng L; Luo WB; Lin H Ai Zheng; 2007 Aug; 26(8):866-9. PubMed ID: 17697549 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]